Surgical simulation steps into a new phase in ophthalmology

Tern plc

In the niche but technically demanding world of ophthalmology, a new approach to training is gaining ground. The traditional reliance on live surgical observation and supervised repetition is being supplemented, and in some cases, pre-empted, by immersive extended reality. At the centre of this evolution is a structured rollout model that reframes simulation as a progressive system of implementation.

Fundamental XR has laid out a clear, phased framework for XR adoption, beginning with pilot testing and moving deliberately through infrastructure deployment, staff onboarding, content calibration, and outcome tracking. This matters because while extended reality has been circulating in healthcare discussions for years, what has often been missing is a replicable model for institutional uptake, something that works beyond a showcase or demo setting.

What makes this opportunity distinctive is that it bypasses much of the hype surrounding general-use XR platforms. Instead, it targets a clear pain point, surgical training bottlenecks, with a solution that is already seeing traction across professional institutions.

Developing and maintaining specialty-specific content, adapting to new surgical techniques and staying aligned with evolving training standards all require sustained investment. But these same factors create defensible barriers to entry. In fields like ophthalmology, where each device or procedure has unique requirements, the demand for high-fidelity simulation remains acute, and unlikely to be met by generalist solutions.

More importantly, this model may not stay confined to one field. If the implementation roadmap proves successful in ophthalmology, there is a clear logic to extending it into other surgical specialities.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Search